Iceland· IS-EU/1/13/842/001-009
Incresync
A pioglitazone and alogliptin product containing pioglitazonum inn hýdróklóríð,alogliptinum inn, registered in Iceland by Takeda Pharma A/S*. The same ATC class is registered in 9 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Pioglitazone and alogliptin is registered in 9 of 19 countries.
Countries holding a registration under ATC A10BD09 (pioglitazone and alogliptin), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 6 of them publish a price we can compare per daily dose
Pioglitazone and alogliptin · ATC A10BD09
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Pioglitazonum INN hýdróklóríð,Alogliptinum INN
- Manufacturer
- Takeda Pharma A/S*
- Country
- Iceland (IS)
- ATC code
- A10BD09
- ATC class
- Pioglitazone and alogliptin
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pioglitazone and alogliptin in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenIncresync 12,5 mg/30 mg Filmdragerad tablettTakeda Pharma A/S
- NetherlandsIncresync 12,5 mg/30 mg filmomhulde tabletTakeda Pharma A/S
- PolandIncresyncTakeda Pharma A/S
- SpainIncresync 12,5 mg/30 mg comprimidos recubiertos con peliculaTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Incresync
- Norway · Incresync
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7dc6bc8d-b05e-4c53-8ead-b8a7f89a95ac GET /v1/drugs/7dc6bc8d-b05e-4c53-8ead-b8a7f89a95ac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "A10BD09",
"marketed": false,
"strength": "12,5 mg/30 mg",
"ma_number": "EU/1/13/842/001-009",
"substance": "Pioglitazonum INN hýdróklóríð,Alogliptinum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "41536"
}See everything about pioglitazone and alogliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.